(Q28257366)
Statements
An open-label phase 2 trial of entospletinib (GS-9973), a selective spleen tyrosine kinase inhibitor, in chronic lymphocytic leukemia (English)
0 references
9 April 2015
0 references
125
0 references
15
0 references
2336-43
0 references